CA2273288A1 - Traitement ou inhibition de la neutropenie - Google Patents
Traitement ou inhibition de la neutropenie Download PDFInfo
- Publication number
- CA2273288A1 CA2273288A1 CA002273288A CA2273288A CA2273288A1 CA 2273288 A1 CA2273288 A1 CA 2273288A1 CA 002273288 A CA002273288 A CA 002273288A CA 2273288 A CA2273288 A CA 2273288A CA 2273288 A1 CA2273288 A1 CA 2273288A1
- Authority
- CA
- Canada
- Prior art keywords
- carbon atoms
- alkyl
- phenyl
- trifluoromethyl
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Méthode pour traiter ou inhiber la neutropénie, ou pour accélérer la récupération de neutrophiles chez le mammifère présentant une insuffisance de ces derniers. Cette méthode consiste à administrer à ce mammifère une quantité efficace d'un composé ou d'un médicament contenant le composé de la formule (I) dans laquelle R¿1? et R¿2? sont chacun sélectionnés indépendamment dans un groupe constitué de l'hydrogène, d'un alkyl comprenant entre 1 et 6 atomes de carbone, de benzoyle éventuellement substitué, (a), (b), (c), (d), (e), (f) et -(CH¿2?)¿n?-R ou R¿1? et R¿2? sont des groupes méthylène réunis pour former un noyau hétérocyclique saturé comprenant 4 à 7 chaînons; R est hydroxy, 4-morpholinyle, 1H-imidazol-1-yl, -CH(alkoxy à 1-6 atomes de carbone)¿2?, .alpha.-hydroxybenzyle ou phényle éventuellement substitué; R¿3? est l'hydrogène ou l'alkyle; R¿4? est l'hydrogène, halogène, alkyle, alkoxy ou trifluorométhyle; R¿5? est l'hydrogène ou l'alkyle; et n=1-3, ou un sel pharmaceutiquement acceptable de ce composé.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US77074396A | 1996-12-19 | 1996-12-19 | |
US08/770,743 | 1996-12-19 | ||
PCT/US1997/023419 WO1998026781A1 (fr) | 1996-12-19 | 1997-12-17 | Traitement ou inhibition de la neutropenie |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2273288A1 true CA2273288A1 (fr) | 1998-06-25 |
Family
ID=25089545
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002273288A Abandoned CA2273288A1 (fr) | 1996-12-19 | 1997-12-17 | Traitement ou inhibition de la neutropenie |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0957918A1 (fr) |
JP (1) | JP2001506998A (fr) |
AR (1) | AR010808A1 (fr) |
AU (1) | AU5611398A (fr) |
CA (1) | CA2273288A1 (fr) |
WO (1) | WO1998026781A1 (fr) |
ZA (1) | ZA9711342B (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2650962C2 (ru) * | 2012-06-07 | 2018-04-18 | Чилдрен'З Хоспитал Лос Анджелес | Способы лечения нейтропении с применением ретиноидных агонистов |
EP3107533A4 (fr) | 2014-02-18 | 2017-10-18 | Children's Hospital Los Angeles | Compositions et méthodes de traitement de la neutropénie |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2615291B1 (fr) * | 1987-05-15 | 1989-07-13 | Thomson Csf | Procede de test en fonctionnement d'un dispositif de visualisation d'informations radar et mise en oeuvre de ce procede |
EP0329940B1 (fr) * | 1988-02-22 | 1994-01-05 | American Cyanamid Company | 5-(Amino substitué)-8-(phényle ou phényle substitué)-3H,6H-1,4,5a,8a-tétraazaacénaphtylène-3-ones |
US4916137A (en) * | 1988-02-22 | 1990-04-10 | American Cyanamid Company | 5-(Substituted-amino)-8-(phenyl or substituted-phenyl)-3H,6H-1,4,5A,8A-tetraazaacenaphthylen-3-ones and treatment of neural behavior disorders |
-
1997
- 1997-12-17 JP JP52798098A patent/JP2001506998A/ja active Pending
- 1997-12-17 ZA ZA9711342A patent/ZA9711342B/xx unknown
- 1997-12-17 AU AU56113/98A patent/AU5611398A/en not_active Abandoned
- 1997-12-17 CA CA002273288A patent/CA2273288A1/fr not_active Abandoned
- 1997-12-17 EP EP97952527A patent/EP0957918A1/fr not_active Withdrawn
- 1997-12-17 WO PCT/US1997/023419 patent/WO1998026781A1/fr not_active Application Discontinuation
- 1997-12-18 AR ARP970105989A patent/AR010808A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
WO1998026781A1 (fr) | 1998-06-25 |
ZA9711342B (en) | 1999-06-17 |
AR010808A1 (es) | 2000-07-12 |
JP2001506998A (ja) | 2001-05-29 |
EP0957918A1 (fr) | 1999-11-24 |
AU5611398A (en) | 1998-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2018394996B2 (en) | Amino-methyl piperidine derivative as kinase inhibitor | |
US11464781B2 (en) | PDE1 inhibitors for ophthalmic disorders | |
US6294565B1 (en) | Methods of combatting infectious diseases using dicationic bis-benzimidazoles | |
US9006258B2 (en) | Method of treating female sexual dysfunction with a PDE1 inhibitor | |
JP5810157B2 (ja) | プロテインキナーゼ阻害剤および処置の方法 | |
AU2005312061B2 (en) | Combinations comprising epothilones and protein tyrosine kinase inhibitors and pharmaceutical uses thereof | |
US20100087450A1 (en) | Organic compounds | |
EP0729758A2 (fr) | Pyrazolopyrimidines et pyrrolopyrimidines pour traiter les troubles neuronaux et autres maladies | |
CA2287122A1 (fr) | Traitement de l'hypertrophie benigne de la prostate avec des agents augmentant les concentrations de gmpc | |
CA2273288A1 (fr) | Traitement ou inhibition de la neutropenie | |
US6051578A (en) | Pyrazolopyrimidines for treatment of CNS disorders | |
US5932585A (en) | Method of treating or inhibiting neutropenia | |
AU2006224623A1 (en) | Method for preventing cardiovascular diseases | |
US20020169154A1 (en) | Novel methods and compositions involving trk tyrosine kinase inhibitors and antineoplastic agents | |
JP2020528052A (ja) | がん治療におけるエリブリン及びサイクリン依存的キナーゼ阻害剤の使用 | |
US4916137A (en) | 5-(Substituted-amino)-8-(phenyl or substituted-phenyl)-3H,6H-1,4,5A,8A-tetraazaacenaphthylen-3-ones and treatment of neural behavior disorders | |
NZ297424A (en) | Use of an aminopurine derivative to treat latent infection of the herpes virus | |
WO2014174478A1 (fr) | Combinaisons pharmaceutiques d'un inhibiteur de la pkc et d'un inhibiteur du récepteur tyrosine-kinase c-met | |
JP2641556B2 (ja) | 5―(置換アミノ)―8―(フエニルまたは置換フエニル)―3H,6H―1,4,5a,8a―テトラアザアセナフチレン―3―オン | |
WO1986007537A2 (fr) | Compositions pharmaceutiques contenant des azanaphtalenes | |
US20030087899A1 (en) | Novel methods for the treatment and prevention of pain | |
CA3155068A1 (fr) | Combinaison de medicaments contenant un agoniste de tlr7 | |
CA2121613A1 (fr) | Compose actif d'une eponge | |
RU97116717A (ru) | 6-замещенные производные пиразоло[3,4-d]пиримидин-4-она, составы на их основе и способы их применения | |
RU97116586A (ru) | 6-арил-пиразоло[3,4-d]пиримидин-4-оны, составы на их основе и способы их применения |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |